Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724769 | 0.87 | TSHR (0.35) | TSHR | |
| SCHEMBL530220 | 0.79 | TSHR (0.33) | TSHR | |
| SCHEMBL145421 | 0.76 | TSHR (0.43) | TSHR | |
| SCHEMBL530219 | 0.76 | TSHR (0.35) | TSHR | |
| SCHEMBL9666541 | 0.74 | EGLN1 (0.38) | — | |
| SCHEMBL22325533 | 0.74 | TSHR (0.52) | TSHR | |
| SCHEMBL890983 | 0.73 | — | — | |
| SCHEMBL530525 | 0.72 | LMNA (0.41) | TSHR | |
| SCHEMBL244781 | 0.72 | TSHR (0.32) | TSHR | |
| SCHEMBL6269584 | 0.72 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138242-A1 | Dihydropyrimidines and uses thereof | MERCK AND CO., INC. | 2004-07-15 | — | — | US | disclosed |
| US-6680323-B2 | SELECTIVE ANTAGONISTS FOR HUMAN ALPHA 1A RECEPTORS; BENIGN PROSTATIC HYPERPLASIA; (+)-1-3-((4-(3,4-DIFLUOROPHENYL)-2,5-DIOXO-1,2,5,7-TETRAHYDRO-4H-FURO(3,4 -D)PYRIMIDINE-3-CARBONYL)AMINO)-PROPYL-4-(2-PYRIDYL)-PIPERIDINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-20 | — | — | US | disclosed |
| EP-1139972-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20010041707-A1 | Dihydropyrimidines and uses thereof | MERCK AND CO., INC | 2001-11-15 | — | — | US | disclosed |
| EP-1139972-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6274585-B1 | BENIGN PROSTATIC HYPERPLASIA TREATMENT | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-08-14 | — | — | US | disclosed |
| WO-2000037026-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138242-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | TSHR 1465/4885 |
| US-20010041707-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | TSHR 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.